GlassScriptPhysician profile
Yunfei Wei
NPI 1801075684
$10,840.35
in general payments reported to CMS, 2019-2025
69 companies · $3,678 in 2025
The $3,678 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,022 · 2020: $1,955 · 2021: $265 · 2022: $97.55 · 2023: $204 · 2024: $619 · 2025: $3,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,478 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,478.28 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $743.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $542.10 | 2019-2025 | Keytruda, Keytruda Qlex, Reblozyl |
| Novartis Pharmaceuticals Corporation | $524.59 | 2019-2025 | |
| Abbvie INC. | $520.91 | 2019-2025 | |
| Eisai INC. | $509.30 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $474.25 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $439.66 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $414.30 | 2019-2025 | Fruzaqla, Iclusig |
| Celgene Corporation | $411.88 | 2019-2021 | |
| Amgen INC. | $406.10 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $394.97 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $288.71 | 2019-2020 | |
| Daiichi Sankyo INC. | $283.08 | 2019-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $274.14 | 2019-2025 | Xtandi, Xospata, Padcev |
| Incyte Corporation | $265.11 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yunfei Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.